vs
Compass, Inc.（COMP）与Steris（STE）财务数据对比。点击上方公司名可切换其他公司
Compass, Inc.的季度营收约是Steris的1.1倍（$1.7B vs $1.5B），Steris净利率更高（12.9% vs -2.5%，领先15.4%），Compass, Inc.同比增速更快（23.1% vs 9.2%），Steris自由现金流更多（$199.5M vs $42.2M），过去两年Compass, Inc.的营收复合增速更高（27.0% vs 15.8%）
Compass, Inc.是美国主营住宅房产经纪业务的企业，其平台旗下有约3.3万名经纪人，大多为独立合同工，运营Compass、21世纪不动产、科威国际不动产、苏富比国际地产、佳士得国际地产等多个知名房产经纪品牌。
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
COMP vs STE — 直观对比
营收规模更大
COMP
是对方的1.1倍
$1.5B
营收增速更快
COMP
高出14.0%
9.2%
净利率更高
STE
高出15.4%
-2.5%
自由现金流更多
STE
多$157.3M
$42.2M
两年增速更快
COMP
近两年复合增速
15.8%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $1.5B |
| 净利润 | $-42.6M | $192.9M |
| 毛利率 | — | 43.8% |
| 营业利润率 | -2.5% | 18.3% |
| 净利率 | -2.5% | 12.9% |
| 营收同比 | 23.1% | 9.2% |
| 净利润同比 | -5.2% | 11.2% |
| 每股收益（稀释后） | $-0.07 | $1.96 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收COMPSTE
| Q4 25 | $1.7B | $1.5B | ||
| Q3 25 | $1.8B | $1.5B | ||
| Q2 25 | $2.1B | $1.4B | ||
| Q1 25 | $1.4B | $1.5B | ||
| Q4 24 | $1.4B | $1.4B | ||
| Q3 24 | $1.5B | $1.3B | ||
| Q2 24 | $1.7B | $1.3B | ||
| Q1 24 | $1.1B | $1.1B |
净利润COMPSTE
| Q4 25 | $-42.6M | $192.9M | ||
| Q3 25 | $-4.6M | $191.9M | ||
| Q2 25 | $39.4M | $177.4M | ||
| Q1 25 | $-50.7M | $145.7M | ||
| Q4 24 | $-40.5M | $173.5M | ||
| Q3 24 | $-1.7M | $150.0M | ||
| Q2 24 | $20.7M | $145.4M | ||
| Q1 24 | $-132.9M | $-1.4M |
毛利率COMPSTE
| Q4 25 | — | 43.8% | ||
| Q3 25 | — | 44.2% | ||
| Q2 25 | — | 45.1% | ||
| Q1 25 | — | 43.3% | ||
| Q4 24 | — | 44.5% | ||
| Q3 24 | — | 43.6% | ||
| Q2 24 | — | 44.7% | ||
| Q1 24 | — | 40.2% |
营业利润率COMPSTE
| Q4 25 | -2.5% | 18.3% | ||
| Q3 25 | -0.4% | 18.2% | ||
| Q2 25 | 1.9% | 17.7% | ||
| Q1 25 | -4.0% | 14.6% | ||
| Q4 24 | -2.9% | 17.9% | ||
| Q3 24 | -0.2% | 16.5% | ||
| Q2 24 | 1.3% | 14.5% | ||
| Q1 24 | -12.5% | 22.0% |
净利率COMPSTE
| Q4 25 | -2.5% | 12.9% | ||
| Q3 25 | -0.2% | 13.1% | ||
| Q2 25 | 1.9% | 12.8% | ||
| Q1 25 | -3.7% | 9.8% | ||
| Q4 24 | -2.9% | 12.7% | ||
| Q3 24 | -0.1% | 11.3% | ||
| Q2 24 | 1.2% | 11.4% | ||
| Q1 24 | -12.6% | -0.1% |
每股收益（稀释后）COMPSTE
| Q4 25 | $-0.07 | $1.96 | ||
| Q3 25 | $-0.01 | $1.94 | ||
| Q2 25 | $0.07 | $1.79 | ||
| Q1 25 | $-0.09 | $1.48 | ||
| Q4 24 | $-0.08 | $1.75 | ||
| Q3 24 | $0.00 | $1.51 | ||
| Q2 24 | $0.04 | $1.46 | ||
| Q1 24 | $-0.27 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $199.0M | $423.7M |
| 总债务越低越好 | — | $1.9B |
| 股东权益账面价值 | $782.0M | $7.2B |
| 总资产 | $1.5B | $10.6B |
| 负债/权益比越低杠杆越低 | — | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资COMPSTE
| Q4 25 | $199.0M | $423.7M | ||
| Q3 25 | $170.3M | $319.2M | ||
| Q2 25 | $177.3M | $279.7M | ||
| Q1 25 | $127.0M | $171.7M | ||
| Q4 24 | $223.8M | $155.2M | ||
| Q3 24 | $211.2M | $172.2M | ||
| Q2 24 | $185.8M | $198.3M | ||
| Q1 24 | $165.9M | $207.0M |
总债务COMPSTE
| Q4 25 | — | $1.9B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $3.1B |
股东权益COMPSTE
| Q4 25 | $782.0M | $7.2B | ||
| Q3 25 | $773.3M | $7.0B | ||
| Q2 25 | $719.9M | $7.0B | ||
| Q1 25 | $635.0M | $6.6B | ||
| Q4 24 | $409.4M | $6.4B | ||
| Q3 24 | $428.0M | $6.6B | ||
| Q2 24 | $398.4M | $6.4B | ||
| Q1 24 | $330.3M | $6.3B |
总资产COMPSTE
| Q4 25 | $1.5B | $10.6B | ||
| Q3 25 | $1.6B | $10.4B | ||
| Q2 25 | $1.6B | $10.4B | ||
| Q1 25 | $1.5B | $10.1B | ||
| Q4 24 | $1.2B | $10.0B | ||
| Q3 24 | $1.2B | $10.2B | ||
| Q2 24 | $1.2B | $10.1B | ||
| Q1 24 | $1.1B | $11.1B |
负债/权益比COMPSTE
| Q4 25 | — | 0.27× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.35× | ||
| Q1 24 | — | 0.50× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.3M | $298.2M |
| 自由现金流经营现金流 - 资本支出 | $42.2M | $199.5M |
| 自由现金流率自由现金流/营收 | 2.5% | 13.3% |
| 资本支出强度资本支出/营收 | 0.2% | 6.6% |
| 现金转化率经营现金流/净利润 | — | 1.55× |
| 过去12个月自由现金流最近4个季度 | $203.3M | $917.1M |
8季度趋势，按日历期对齐
经营现金流COMPSTE
| Q4 25 | $45.3M | $298.2M | ||
| Q3 25 | $75.5M | $287.8M | ||
| Q2 25 | $72.8M | $420.0M | ||
| Q1 25 | $23.1M | $260.8M | ||
| Q4 24 | $30.5M | $332.8M | ||
| Q3 24 | $37.4M | $250.7M | ||
| Q2 24 | $45.0M | $303.7M | ||
| Q1 24 | $8.6M | $254.8M |
自由现金流COMPSTE
| Q4 25 | $42.2M | $199.5M | ||
| Q3 25 | $73.6M | $201.3M | ||
| Q2 25 | $68.0M | $326.4M | ||
| Q1 25 | $19.5M | $189.9M | ||
| Q4 24 | $26.7M | $243.6M | ||
| Q3 24 | $32.8M | $148.8M | ||
| Q2 24 | $40.4M | $195.7M | ||
| Q1 24 | $5.9M | $163.3M |
自由现金流率COMPSTE
| Q4 25 | 2.5% | 13.3% | ||
| Q3 25 | 4.0% | 13.8% | ||
| Q2 25 | 3.3% | 23.5% | ||
| Q1 25 | 1.4% | 12.8% | ||
| Q4 24 | 1.9% | 17.8% | ||
| Q3 24 | 2.2% | 11.2% | ||
| Q2 24 | 2.4% | 15.3% | ||
| Q1 24 | 0.6% | 14.6% |
资本支出强度COMPSTE
| Q4 25 | 0.2% | 6.6% | ||
| Q3 25 | 0.1% | 5.9% | ||
| Q2 25 | 0.2% | 6.7% | ||
| Q1 25 | 0.3% | 4.8% | ||
| Q4 24 | 0.3% | 6.5% | ||
| Q3 24 | 0.3% | 7.7% | ||
| Q2 24 | 0.3% | 8.4% | ||
| Q1 24 | 0.3% | 8.2% |
现金转化率COMPSTE
| Q4 25 | — | 1.55× | ||
| Q3 25 | — | 1.50× | ||
| Q2 25 | 1.85× | 2.37× | ||
| Q1 25 | — | 1.79× | ||
| Q4 24 | — | 1.92× | ||
| Q3 24 | — | 1.67× | ||
| Q2 24 | 2.17× | 2.09× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
COMP
暂无分部数据
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
